Social functioning as an outcome measure in schizophrenia studies

被引:268
作者
Burns, T.
Patrick, D.
机构
[1] Univ Oxford, Dept Psychiat, Oxford, England
[2] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA
[3] Univ Washington, Seattle Qual Life Grp, Seattle, WA 98195 USA
关键词
antipsychotics; disability; personal and social performance scale; psychometric properties; schizophrenia; social functioning;
D O I
10.1111/j.1600-0447.2007.01108.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Deficits in social functioning are a core feature of schizophrenia. Method: A literature search of English language articles published between January 1990 and December 2006 was undertaken to identify: i) scales used most frequently to assess social functioning in schizophrenia; and ii) the most frequently used social functioning scales in randomized, controlled trials of antipsychotics. A further search (without time limits) examined their psychometric properties. Results: A total of 301 articles employed social functioning scales in the assessment of schizophrenia. These contained 87 potentially relevant measures. Only 14 randomized, controlled studies of antipsychotic agents were identified that examined social functioning. Scales varied greatly in terms of measurement approach, number and types of domains covered and scoring systems. A striking lack of data on psychometric properties was observed. Conclusion: Limited consensus on the definition and measurement of social functioning exists. The Personal and Social Performance Scale is proposed as a useful tool in future research.
引用
收藏
页码:403 / 418
页数:16
相关论文
共 97 条
[11]   Development and validation of a social functioning scale, the social adaptation self-evaluation scale [J].
Bosc, M ;
Dubini, A ;
Polin, V .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 :S57-S70
[12]   Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia [J].
Bouchard, RH ;
Mérette, C ;
Pourcher, E ;
Demers, MF ;
Villeneuve, J ;
Roy-Gagnon, MH ;
Gauthier, Y ;
Cliche, D ;
Labelle, A ;
Filteau, MJ ;
Roy, MA ;
Maziade, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (03) :295-304
[13]   TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA WITH AMISULPRIDE [J].
BOYER, P ;
LECRUBIER, Y ;
PUECH, AJ ;
DEWAILLY, J ;
AUBIN, F .
BRITISH JOURNAL OF PSYCHIATRY, 1995, 166 :68-72
[14]   Initial and final work performance in schizophrenia: Cognitive and symptom predictors [J].
Bryson, G ;
Bell, MD .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 2003, 191 (02) :87-92
[15]   Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials [J].
Chakos, M ;
Lieberman, J ;
Hoffman, E ;
Bradford, D ;
Sheitman, B .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (04) :518-526
[16]   Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study [J].
Christensen, AF ;
Poulsen, J ;
Nielsen, CT ;
Bork, B ;
Christensen, A ;
Christensen, M .
ACTA PSYCHIATRICA SCANDINAVICA, 2006, 113 (02) :148-153
[17]   Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia [J].
Colonna, L ;
Saleem, P ;
Dondey-Nouvel, L ;
Rein, W .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2000, 15 (01) :13-22
[18]   A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia [J].
Csernansky, JG ;
Mahmoud, R ;
Brenner, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (01) :16-22
[19]   Relapse and rehospitalisation rates in patients with schizophrenia - Effects of second generation antipsychotics [J].
Csernansky, JG ;
Schuchart, EK .
CNS DRUGS, 2002, 16 (07) :473-484
[20]   Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study [J].
Davidson, Michael ;
Emsley, Robin ;
Michelle, Kramer ;
Ford, Lisa ;
Pan, Guohua ;
Lim, Pilar ;
Eerdekens, Marile .
SCHIZOPHRENIA RESEARCH, 2007, 93 (1-3) :117-130